医薬品リファレンス
Ciltacabtagene autoleucel
Ciltacabtagene autoleucel is a medicine in the class miscellaneous. It is used for multiple myeloma.
- 薬効分類: Miscellaneous
- 効能・効果: multiple myeloma
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Miscellaneous
- ATCコード
- L01XL05
- 既知の相互作用
- 68 (重大: 46 · 中等度: 21 · 軽度: 1)
- 商品名
- 1
- 国・市場
- 1
何に使われるか
作用のしくみ
BCMA-directed, genetically modified autologous T cell immunotherapy. The CAR has two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain and a CD3-zeta signaling domain. On binding BCMA-expressing cells, the CAR promotes T cell activation, expansion and elimination of target cells.
成人の通常用量（添付文書の要約）
Relapsed or refractory multiple myeloma: single IV infusion of 0.5–1.0×10^6 CAR-positive viable T cells per kg body weight; maximum 1×10^8 CAR-positive viable T cells per single infusion
妊娠と授乳
- 妊娠
- Unsafe No data in pregnancy. CAR-T cells may cross the placenta and cause fetal B-cell depletion and low antibody levels. Not recommended in pregnancy or without contraception; confirm a negative pregnancy test before treatment.
- 授乳
- Unknown No information on presence in milk or effects on the infant. Weigh breastfeeding benefits against the mother's need; follow the guidance for the lymphodepleting chemotherapy.
報告されている副作用
- Pyrexia
- Cytokine release syndrome
- Hypogammaglobulinemia
- Hypotension
- Musculoskeletal pain
- Fatigue
警告（枠囲み警告）
- Fatal or life-threatening CRS occurred; do not give to patients with active infection or inflammatory disorders; treat severe CRS with tocilizumab or tocilizumab and corticosteroids. Fatal or life-threatening ICANS, parkinsonism and Guillain-Barré syndrome occurred; monitor for neurologic events. HLH/MAS, prolonged and recurrent cytopenias, immune effector cell-associated enterocolitis, and secondary hematological malignancies (MDS, AML, T-cell malignancies) have occurred.
注意が必要な方
- Increased early mortality in CARTITUDE-4: 14% of deaths in the CARVYKTI arm versus 12% in the control arm within 10 months
- Monitor at least daily for 7 days for CRS and neurologic toxicities; confirm that a minimum of two doses of tocilizumab are available before infusion
- Prolonged and recurrent cytopenias; monitor blood counts before and after infusion
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (68)
- Adalimumab + Ciltacabtagene autoleucel Major
- Anti-thymocyte + Ciltacabtagene autoleucel Major
- Azathioprine + Ciltacabtagene autoleucel Major
- Baricitinib + Ciltacabtagene autoleucel Major
- Basiliximab + Ciltacabtagene autoleucel Major
- Bendamustine + Ciltacabtagene autoleucel Major
- Capecitabine + Ciltacabtagene autoleucel Major
- Carboplatin + Ciltacabtagene autoleucel Major
- Certolizumab pegol + Ciltacabtagene autoleucel Major
- Chlorambucil + Ciltacabtagene autoleucel Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Ciltacabtagene autoleucelの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
よくある質問
What is Ciltacabtagene autoleucel used for?
Ciltacabtagene autoleucel is a medicine in the class miscellaneous. It is used for Multiple myeloma.
What side effects have been reported with Ciltacabtagene autoleucel?
Pyrexia, Cytokine release syndrome, Hypogammaglobulinemia, Hypotension, Musculoskeletal pain, Fatigue. Serious warning: Fatal or life-threatening CRS occurred; do not give to patients with active infection or inflammatory disorders; treat severe CRS with tocilizumab or tocilizumab and corticosteroids.
Can Ciltacabtagene autoleucel be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. No data in pregnancy. CAR-T cells may cross the placenta and cause fetal B-cell depletion and low antibody levels. Not recommended in pregnancy or without contraception; confirm a negative pregnancy test before treatment. Breastfeeding: Unknown. No information on presence in milk or effects on the infant. Weigh breastfeeding benefits against the mother's need; follow the guidance for the lymphodepleting chemotherapy.
What does Ciltacabtagene autoleucel interact with?
MediHelp lists 68 known interactions for Ciltacabtagene autoleucel. Major: 46 · Moderate: 21 · Minor: 1. The most serious include Adalimumab, Anti-thymocyte, Azathioprine.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
